Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy

Table 3 Multivariate survival analysis

	Promoter methylation			Protein expression
	HR	95% CI	P value	HR	95% CI	P value
Variable without interaction term
Gender	0.83	0.41-1.52	0.44	0.95	0.46-1.76	0.86
Age	1.10	1.01-1.20	0.002	1.10	1.01-1.12	0.002
Performance status	0.98	0.92-1.02	0.001	0.98	0.92-1.02	0.001
Extent of surgery	0.14	0.08-0.22	< 0.001	0.14	0.08-0.24	< 0.001
MGMT promoter	1.32	1.11-1.56	0.012	1.32	1.11-1.55	0.012
TMZ therapy	0.29	0.14-0.50	< 0.001	0.29	0.14-0.49	< 0.001
Promoter methylation	0.62	0.31-1.19	0.15
Protein expression				2.11	1.09-3.77	0.02
Variable with interaction terms
Gender	0.83	0.41-1.55	0.46	1.02	0.50-1.87	0.95
Age	1.10	1.01-1.20	0.002	1.10	1.01-1.22	0.001
Performance status	0.98	0.92-1.03	0.002	0.98	0.92-1.02	0.001
Extent of surgery	0.14	0.08-0.22	< 0.001	0.14	0.08-0.34	< 0.001
MGMT promoter	1.32	1.11-1.57	0.018	1.32	1.11-1.55	0.012
TMZ therapy	0.32	0.11-0.83	0.02	0.11	0.03-0.25	< 0.001
Promoter methylation	0.67	0.59-2.91	0.33
Protein expression				1.06	0.45-2.11	0.45
Promoter methylation × TMZ therapy			0.83
Protein expression × TMZ therapy						0.004

ISSN: 1479-5876